Literature DB >> 33369488

A Randomized Controlled Trial of Preoperative Prophylactic Antibiotics for Percutaneous Nephrolithotomy in Moderate to High Infectious Risk Population: A Report from the EDGE Consortium.

Roger L Sur1, Amy E Krambeck2, Tim Large2, Seth K Bechis1, David F Friedlander3, Manoj Monga1, Ryan S Hsi4, Nicole L Miller4, Ben H Chew5, Dirk Lange6, Bodo Knudsen7, Michael W Sourial6, Mitchell R Humphreys7, Karen L Stern7, Ojas Shah8, Joel E Abbott1, Garen Abedi1.   

Abstract

PURPOSE: Postoperative infectious related complications are not uncommon after percutaneous nephrolithotomy. Previously, we noted that 7 days of antibiotics did not decrease sepsis rates compared to just perioperative antibiotics in a low risk percutaneous nephrolithotomy population. This study aimed to compare the same regimens in individuals at moderate to high risk for sepsis undergoing percutaneous nephrolithotomy.
MATERIALS AND METHODS: Patients were prospectively randomized in this multi-institutional study to either 2 days or 7 days of preoperative antibiotics. Enrolled patients had stones requiring percutaneous nephrolithotomy and had either a positive preoperative urine culture or existing indwelling urinary drainage tube. Primary outcome was difference in sepsis rates between the groups. Secondary outcomes included rate of nonseptic bacteriuria, stone-free rate and length of stay.
RESULTS: A total of 123 patients at 7 institutions were analyzed. There was no difference in sepsis rates between groups on univariate analysis. Similarly, there were no differences in nonseptic bacteriuria, stone-free rate and length of stay. On multivariate analysis, 2 days of antibiotics increased the risk of sepsis compared to 7 days of antibiotics (OR 3.1, 95% CI 1.1-8.9, p=0.031). Patients receiving antibiotics for 2 days had higher rates of staghorn calculus than the 7-day group (58% vs 32%, p=0.006) but post hoc subanalysis did not demonstrate increased sepsis in the staghorn only group.
CONCLUSIONS: Giving 7 days of preoperative antibiotics vs 2 days decreases the risk of sepsis in moderate to high risk percutaneous nephrolithotomy patients. Future guidelines should consider infectious risk stratification for percutaneous nephrolithotomy antibiotic recommendations.

Entities:  

Keywords:  anti-bacterial agents; nephrolithiasis; nephrolithotomy; percutaneous; sepsis; urolithiasis

Year:  2020        PMID: 33369488     DOI: 10.1097/JU.0000000000001582

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  5 in total

1.  Preoperative antibiotic therapy exceeding 7 days can minimize infectious complications after percutaneous nephrolithotomy in patients with positive urine culture.

Authors:  Peng Xu; Shike Zhang; Yuyan Zhang; Jinkun Huang; Guohua Zeng; Wenqi Wu; Tao Zeng; Dong Chen; Weizhou Wu; Hans-Goran Tiselius; Shujue Li
Journal:  World J Urol       Date:  2021-09-22       Impact factor: 4.226

2.  Nephrostomy before percutaneous nephrolithotomy is a new approach in preventing postoperative infectious complications in patients with ESBL-positive E. coli.

Authors:  Guolin Lei
Journal:  World J Urol       Date:  2021-10-11       Impact factor: 4.226

3.  Salvage versus primary holmium laser enucleation of the prostate: trends, outcomes and safety analysis.

Authors:  Adri M Durant; Jonathan Moore; Sandeep Voleti; Sarah Wu; Lanyu Mi; Gopal Narang; Scott Cheney; Mitchell Humphreys
Journal:  World J Urol       Date:  2022-07-22       Impact factor: 3.661

4.  Antibiotic prophylaxis for percutaneous nephrolithotomy: An updated systematic review and meta-analysis.

Authors:  Hae Do Jung; Kang Su Cho; Young Joon Moon; Doo Yong Chung; Dong Hyuk Kang; Joo Yong Lee
Journal:  PLoS One       Date:  2022-04-15       Impact factor: 3.240

5.  The antibiotic strategies during percutaneous nephrolithotomy in China revealed the gap between the reality and the urological guidelines.

Authors:  Shike Zhang; Gonghui Li; Ludong Qiao; Dehui Lai; Zhican He; Lingyue An; Peng Xu; Hans-Göran Tiselius; Guohua Zeng; Junhua Zheng; Wenqi Wu
Journal:  BMC Urol       Date:  2022-08-30       Impact factor: 2.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.